NasdaqGS:RGENLife Sciences
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit
Repligen (RGEN) just widened its bioprocessing toolkit with three new chromatography resins aimed at gene therapy workflows, a move that quietly matters for both long term growth expectations and the stock’s quality story.
See our latest analysis for Repligen.
Repligen’s new resin launches land after a bumpy stretch, with a strong 90 day share price return of 28.96 percent off a softer year to date base. However, the 1 year total shareholder return of 7.63 percent still masks a weaker multi...